Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 239

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 239
---
 pro forma combined statements of operations for the six -monthperiod ended December31, 2024, combine: •the historical unaudited combined statement of operations of OmnigenicsAI for the six -monthperiod ended December31, 2024; and •the historical statement of operations of APx for the six -monthperiod ended December31, 2024, using its audited statement of operations for the fiscal year ended December31, 2024, deducting its unaudited statement of operations for the six -monthperiod ended June30, 2024. The following unaudited pro forma condensed combined statements of operations for the year ended June 30, 2024, combine: •the historical audited combined statement of operations of OmnigenicsAI for year ended June30, 2024; and •the historical statement of operations of APx for the twelve -monthperiod ended June30, 2024 using its unaudited consolidated statements of operations for the six -monthperiod ended June30, 2024, added with its audited consolidated statements of operations for the fiscal year ended December31, 2023, deducting its unaudited consolidated statements of operations for the six -monthperiod ended June30, 2023. The unaudited pro forma combined statement of operations was prepared giving pro forma effect to the Business Combination as if it had occurred on July 1, 2023, the beginning of the earliest period presented. For more information about the Business Combination see “ The Business Combination.” The unaudited pro forma combined financial information has been prepared assuming: • Scenario 1 — Assuming no redemptions for cash: This presentation assumes that no SPAC Shareholders exercise redemption rights with respect to their SPAC Ordinary Shares upon consummation of the Business Combination and considers that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of up to $10,000,000 to OmnigenicsAI Corp. See “ Certain Agreements Related to the Business Combination — Backstop Agreement;” • Scenario 2 — Assuming redemptions of 50% of the outstanding Public Shares for cash: This presentation assumes that holders of Public Shares exercise their redemption rights with respect to 50% of the Public Shares upon consummation of the Business Combination at a redemption price of approximately $12.05 per share as of December31, 2024 (fair value as of said date). Scenario 2 includes all adjustments contained in Scenario 1 and